Why the study?
Does levosimendan improve coronary flow, cardiac performance, and neurohormonal activation in patients with advanced heart failure?
Population
42 patients with advanced heart failure, NYHA class III-IV, and a left ventricular ejection fraction 25+/-6%
Comparison
Levosimendan 0.1 microg/kg/min for 24 hours vs Placebo for 24 hours
Design
RCT, randomised
Follow-up
24 hours
Authors
Loading...
Supports short-term levosimendan in advanced HF; extends RCT evidence on coronary flow and surrogate hemodynamic benefits.
Does levosimendan improve coronary flow, cardiac performance, and neurohormonal activation in patients with advanced heart failure?
A 24-hour infusion of levosimendan significantly improves coronary flow, cardiac performance, and neurohormonal profiles in patients with advanced heart failure compared to placebo.
Ikonomidis et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: